
pmid: 29601998
Growth hormone (GH) and IGF-I levels in serum are used as biomarkers in the diagnosis and management of GH-related disorders but have not been subject to structured validation. Auxological parameters in children and changes in body composition in adults, as well as metabolic parameters and patient related outcomes are used as clinical and surrogate endpoints. New treatment options, such as long acting GH and GH antagonists, require reevaluation of the currently used biochemical biomarkers. This article will review biomarkers, surrogate endpoints and clinical endpoints related to GH treatment in children and adults as well as in acromegaly.
Adult, Hormone Replacement Therapy, Human Growth Hormone, Human Growth Hormone/therapeutic use, Outcome Assessment (Health Care)/methods, Biomarkers/analysis, Outcome Assessment, Health Care, Humans, Growth Disorders/drug therapy, Child, Biomarkers, Growth Disorders
Adult, Hormone Replacement Therapy, Human Growth Hormone, Human Growth Hormone/therapeutic use, Outcome Assessment (Health Care)/methods, Biomarkers/analysis, Outcome Assessment, Health Care, Humans, Growth Disorders/drug therapy, Child, Biomarkers, Growth Disorders
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
